I was under the impression that the street rewarded companies like Threshold or Oncogenex because there was an real chance that they wouldn't have been able to conduct a successful transaction.
We have to remember that just a few months ago we thought many of these small bio's would not be able to raise cash.
Momenta wasn't in this class.
So in short, many of these transactions were an lifeline for the company and for others it was no more than dilution.
Market Data 
Markets 
AI
